Today's pre-market stock movers: BNTX, JBLU, DWAC, SAVE and more

• $Axsome Therapeutics (AXSM.US)$ +39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder)

• $Capricor Therapeutics (CAPR.US)$ +4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open Label Extension Study)

• $Zai Lab (ZLAB.US)$ +3.7% (reports primary listing on the Main Board of The Stock Exchange of HongKong)

• $The AES Corp (AES.US)$ +2.7% (discloses a pre-tax impairment charge in the range of $450 million to $550 million related to Bulgaria's National Recovery and Resilience plan which commits the country to cease electricity generation using coal as a fuel source by 2038)

• $BioNTech (BNTX.US)$ +2.1% (Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron)

• $Aclaris Therapeutics (ACRS.US)$ +2% (appoints Gail Cawkwell, MD, PhD, as Chief Medical Officer)

• $EVgo Inc (EVGO.US)$ +2% (EVgo Inc. and $General Motors (GM.US)$ announce availability of Plug and Charge for all GM EVs with DC fast ­charging capability on the EVgo network)

• $Day One Biopharmaceuticals (DAWN.US)$ +1.6% (issues slides and includes clinical update)

• $JetBlue Airways (JBLU.US)$ +1.5% (Spirit Airlines determines JetBlue's revised offer is not a Superior Proposal)

• $TG Therapeutics (TGTX.US)$ +1.4% (presentation of exploratory analyses from the ULTIMATE I & II Phase 3 trials of ublituximab)

• $Vir Biotechnology (VIR.US)$ +1% (New Clinical Data From its Broad Hepatitis B Program)

• $BWX Technologies (BWXT.US)$ +1% (announces that subsidiary BWXT Medical Ltd. has executed a commercial agreement with $BAYER AG (BAYZF.US)$ to supply high-purity Actinium-225)

• $AutoZone (AZO.US)$ +1.9% (upgraded to Buy from Neutral at Goldman)

• $Borqs Technologies (BRQS.US)$ -25.8% (announces reverse stock split)

• $Nuvation Bio (NUVB.US)$ -18.4% (FDA places partial clinical hold on Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer)

• $SIGA Technologies (SIGA.US)$ -11.4% (WHO says that monkeypox does not constitute a public health emergency of international concern)

• $Digital World Acquisition Corp (DWAC.US)$ -8.6% (files registration statement on Form S-4)

• $Spirit Airlines (SAVE.US)$ -5.3% (Spirit Airlines determines JetBlue's revised offer is not a Superior Proposal)

• $Sitio Royalties (STR.US)$ -4.8% (announces highly accretive Permian Basin acquisitions; updates guidance)

• $Altair Engineering (ALTR.US)$ -3.6% (closes private offering of $200 mln convertible senior notes; Court lifts final injunction in favor of Altair in World Programming Case; also downgraded to Sell from Neutral at Goldman)

• $BridgeBio Pharma (BBIO.US)$ -2.5% (Phase 1 Data and Phase 2/3 Trial Design for BBP-711)

• $Frontier Group (ULCC.US)$ -1.8% (Spirit Airlines determines JetBlue's revised offer is not a Superior Proposal)

• $Albemarle (ALB.US)$ -1.7% (initiated with an Underperform at Credit Suisse)